
Novo Nordisk and Eli Lilly are battling it out on the billion-dollar obesity market, and Zealand Pharma wants in.
The biotech company, which is based in Denmark, has released phase I data on its GLP-1/GLP-2 dual agonist dapiglutide within the obesity indication, and announced that a phase II trial will now be initiated.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app